[1]CurrentPatentAssignee:UNIVERSITYOFMISSOURISYSTEM-WO2014/4854,2014,A1
[1]CurrentPatentAssignee:UNIVERSITYOFMISSOURISYSTEM-WO2014/4854,2014,A1Locationinpatent:Paragraph0199
[1]CurrentPatentAssignee:UNIVERSITYOFMISSOURISYSTEM-WO2014/4854,2014,A1
[1]CurrentPatentAssignee:UNIVERSITYOFMISSOURISYSTEM-WO2014/4854,2014,A1
[1]CurrentPatentAssignee:UNIVERSITYOFMISSOURISYSTEM-WO2014/4854,2014,A1
Title: Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.
Journal: Journal of medicinal chemistry 20120614
Title: Oxidosqualene cyclase from Saccharomyces cerevisiae, Trypanosoma cruzi, Pneumocystis carinii and Arabidopsis thaliana expressed in yeast: a model for the development of novel antiparasitic agents.
Journal: Bioorganic & medicinal chemistry letters 20090201
Title: Synthesis and structure-activity studies of novel orally active non-terpenoic 2,3-oxidosqualene cyclase inhibitors.
Journal: Journal of medicinal chemistry 20030717
Title: Morand OH, et al. Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. J Lipid Res. 1997 Feb;38(2):373-90.
Title: Liang Y, et al. Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells. Onco Targets Ther. 2016 May 30;9:3223-32
Title: Liang Y, et al. Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071. Breast Cancer Res Treat. 2014 Jul;146(1):51-62.
Title: Chuang JC, et al. Sustained and selective suppression of intestinal cholesterol synthesis by Ro 48-8071, an inhibitor of 2,3-oxidosqualene:lanosterol cyclase, in the BALB/c mouse. Biochem Pharmacol. 2014 Apr 1;88(3):351-63.